Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 626491
                    [Title] => Extending the life of people with lung cancer
                    [Summary] => 
MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung cancer.
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

METMAB

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 689458
                    [Title] => Roche bares study results on lung cancer medicine
                    [Summary] => 
Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2011-05-26 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 626491
                    [Title] => Extending the life of people with lung cancer
                    [Summary] => 
MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung cancer.
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche bares study results on lung cancer medicine

May 26, 2011 - 12:00am

Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small...

Science and Environment

Extending the life of people with lung cancer

November 4, 2010 - 12:00am

MILAN, Italy — Roche has released new data for its new investigational compound at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung c...

Science and Environment